Radiopharmaceutical therapy and radioembolization: Clinical guidance for medical physicists in radiation oncology.

Pract Radiat Oncol

Northwell Health, Department of Radiology, 200 Marcus Avenue, New Hyde Park, NY 11040.

Published: December 2024

Recent advances in radiopharmaceutical therapy (RPT) and radioembolization (RE) will make these forms of therapy more prevalent in radiation oncology and nuclear medicine clinics. This article guides medical physicists in radiation oncology by summarizing current RPT and RE techniques, processes, safety, quality assurance, equipment, etc. The summarized guidance, which addresses technical considerations, may be applied broadly to develop a clinical RPT/RE program that offers multiple types of such therapies.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.prro.2024.12.005DOI Listing

Publication Analysis

Top Keywords

radiation oncology
12
radiopharmaceutical therapy
8
medical physicists
8
physicists radiation
8
therapy radioembolization
4
radioembolization clinical
4
clinical guidance
4
guidance medical
4
oncology advances
4
advances radiopharmaceutical
4

Similar Publications

De-Escalation of Nodal Surgery in Clinically Node-Positive Breast Cancer.

JAMA Surg

January 2025

Breast Unit, Department of General Surgery, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Türkiye.

Importance: Increasing evidence supports the oncologic safety of de-escalating axillary surgery for patients with breast cancer after neoadjuvant chemotherapy (NAC).

Objective: To evaluate the oncologic outcomes of de-escalating axillary surgery among patients with clinically node (cN)-positive breast cancer and patients whose disease became cN negative after NAC (ycN negative).

Design, Setting, And Participants: In the NEOSENTITURK MF-1803 prospective cohort registry trial, patients from 37 centers with cT1-4N1-3M0 disease treated with sentinel lymph node biopsy (SLNB) or targeted axillary dissection (TAD) alone or with ypN-negative or ypN-positive disease after NAC were recruited between February 15, 2019, and January 1, 2023, and evaluated.

View Article and Find Full Text PDF

Importance: Evolving breast cancer treatments have led to improved outcomes but carry a substantial financial burden. The association of treatment costs with the cost-effectiveness of screening mammography is unknown.

Objective: To determine the cost-effectiveness of population-based breast cancer screening in the context of current treatment standards.

View Article and Find Full Text PDF

Importance: Cardiovascular disease (CVD) and cancer are the leading causes of mortality in the US. Large-scale population-based and mechanistic studies support a direct effect of CVD on accelerated tumor growth and spread, specifically in breast cancer.

Objective: To assess whether individuals presenting with advanced breast cancers are more likely to have prevalent CVD compared with those with early-stage breast cancers at the time of diagnosis.

View Article and Find Full Text PDF

Importance: The current standard-of-care salvage therapy in relapsed/refractory classic Hodgkin lymphoma (cHL) includes consolidation high-dose chemotherapy (HDCT)/autologous stem cell transplant (aSCT).

Objective: To investigate whether presalvage risk factors and fludeoxyglucose-18 (FDG) positron emission tomography (PET) response to reinduction chemotherapy can guide escalation or de-escalation between HDCT/aSCT or transplant-free consolidation with radiotherapy to minimize toxic effects while maintaining high cure rates.

Design, Setting, And Participants: EuroNet-PHL-R1 was a nonrandomized clinical trial that enrolled patients younger than 18 years with first relapsed/refractory cHL across 68 sites in 13 countries in Europe between January 2007 and January 2013.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!